AbClon, Inc. engages in the development, manufacture and sale of antibody drugs. It operates through the Therapeutic antibody and Bio CRO businesses. Its offers antibodies and detection kits. The company was founded by Carl Erik Mathias Uhlén and Jong-Seo Lee on June 25, 2010 and is headquartered in Seoul, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company